DE VITA, Ferdinando
 Distribuzione geografica
Continente #
EU - Europa 5.193
NA - Nord America 4.578
AS - Asia 553
AF - Africa 17
SA - Sud America 14
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 5
Totale 10.369
Nazione #
US - Stati Uniti d'America 4.454
IE - Irlanda 1.731
UA - Ucraina 754
IT - Italia 672
GB - Regno Unito 611
DE - Germania 444
FR - Francia 372
CN - Cina 327
SE - Svezia 204
FI - Finlandia 200
GR - Grecia 134
TR - Turchia 120
CA - Canada 118
VN - Vietnam 54
PL - Polonia 27
BE - Belgio 24
KR - Corea 16
SG - Singapore 15
SC - Seychelles 13
JP - Giappone 8
MX - Messico 6
NZ - Nuova Zelanda 6
BR - Brasile 5
EU - Europa 5
IR - Iran 5
NL - Olanda 5
ES - Italia 4
PE - Perù 4
AU - Australia 3
CL - Cile 2
CZ - Repubblica Ceca 2
IN - India 2
MK - Macedonia 2
PK - Pakistan 2
RS - Serbia 2
UG - Uganda 2
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
CO - Colombia 1
HK - Hong Kong 1
IL - Israele 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 10.369
Città #
Dublin 1.724
Jacksonville 1.174
Chandler 806
Princeton 245
Medford 216
New York 151
Caserta 143
Ann Arbor 142
Roxbury 142
Boardman 137
Bremen 134
San Mateo 125
Elora 98
Wilmington 97
Woodbridge 74
Naples 72
Beijing 62
Nanjing 61
Dong Ket 52
Cambridge 51
Des Moines 50
Napoli 46
Jinan 35
Mountain View 29
Ashburn 27
Kraków 26
Brussels 23
Houston 20
Norwalk 19
Düsseldorf 15
Helsinki 15
Tianjin 15
Aiello Del Sabato 14
Nanchang 13
Shenyang 13
Auburn Hills 12
Milan 12
Hangzhou 11
Lanzhou 11
Ottawa 11
Los Angeles 10
Rome 10
Taizhou 10
Zhengzhou 10
Changsha 8
Ningbo 8
Redwood City 8
Singapore 8
Aversa 7
Guangzhou 7
Jiaxing 7
Kunming 7
Lappeenranta 7
Hebei 6
Munich 6
Parma 6
Salerno 6
Boydton 5
Changchun 5
Haikou 5
Hanover 5
Marigliano 5
Sennori 5
Shanghai 5
Taiyuan 5
Benevento 4
Casoria 4
Hefei 4
Lima 4
Seattle 4
Somma Vesuviana 4
Trieste 4
Amsterdam 3
Arzignano 3
Atlanta 3
Avellino 3
Battipaglia 3
Calvizzano 3
Canicattì 3
Cattolica 3
Ercolano 3
Gunzenhausen 3
Jesi 3
London 3
Mugnano Di Napoli 3
Pomezia 3
Potenza 3
San Nicola la Strada 3
Toronto 3
Viareggio 3
Xiangfen 3
Andover 2
Athens 2
Bagnoli Irpino 2
Bari 2
Berlin 2
Brno 2
Catania 2
Fairfield 2
Ferrara 2
Totale 6.397
Nome #
ONCOLOGIA MEDICA 143
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 99
MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib 85
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 83
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 80
Predictive biomarkers along gastric cancer pathogenetic pathways 78
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 78
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 74
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 74
Amifostine: a selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review) 73
Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review. 71
Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis 70
Clinical management of advanced gastric cancer: Role of new molecular drugs. 70
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 70
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 70
TRASTUZUMAB RESISTANCE IN BREAST CANCER 70
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 68
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 68
Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. 67
Farmacogenomica e cancro colorettale 66
CD 26-positive/CD 326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence 65
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 64
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 63
Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer. 63
Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome 62
Treatment of gastric cancer. 62
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 62
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 61
Different Biomarkers address different colorectal cancer stem cell populations: who's the killer? 61
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 61
Analysis of neurothelin expression in neoplastic cells derived from gastrointestinal tract tumors 61
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 59
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 59
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 58
Chemoradiotherapy as adjuvant treatment of gastric cancer 58
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival 58
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 57
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 57
Cardiotossicità da antracicline: attualità e prospettive 57
PROSPETTIVE DELLA TERAPIA NEOADIUVANTE NEL CANCRO ESOFAGEO AVANZATO 57
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 57
The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. 56
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 56
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 56
Behavior of circulating CD4+CD25+FOXP3* regulatory T cells in colon cancer patients undergoing surgery 56
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 56
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 56
Determination of molecular marker expression can predict clinical outcome in colon carcinomas 55
Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion 55
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 55
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 55
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 55
Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience 55
Integrated therapy in localized gastric cancer: targeted and tailored approach. 54
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group 54
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 54
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 54
Ventricular repolarization time indexes following anthracycline treatment 54
Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer 54
The over-the-scope-clip (OTSC) system is effective in the treatment of chronic esophago-jejunal anastomotic leakage 54
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 54
A rare case of extraovarian primary peritoneal carcinoma in a 72 year-old woman 53
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 53
PERSPECTIVES OF THE NEOADJUANT THERAPY IN ADVANCED ESOPHAGEAL CARCINOMA 53
Il linfoma primitivo della parotide: una localizzazione infrequente 53
Il trattamento delle neoplasie polmonari nell’anziano 53
Serum interleukin-10 is an independent prognostic factor in advanced solid tumors 52
Integrated therapy in localized gastric cancer: targeted and tailored approach. Letter to the editor 52
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 52
Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients 52
Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis 52
Adult Wilms' tumor: a case report 52
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 52
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. 51
A true splenic cyst producing carboydrate antigen 19-9 and cancer antigen 50 and 125,but not interleukin 10 51
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies 51
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery 51
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. 51
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study 51
Carcinoma dell'esofago 51
Insulin-like growth factor-1 bioactivity plays a prosurvival role in older participants 50
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 50
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery 50
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study 50
Targeting EGFR in Pancreatic Cancer Treatment. 50
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 50
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. 49
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. 49
Cetuximab in the treatment of colorectal cancer. 49
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 49
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 49
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 49
Malignant transformation in non-recurrent peritoneal cystic mesothelioma Our experience and review of the literature 49
Sequential treatment with pazopanib and everolimus in metastatic renal cell carcinoma 49
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 49
Preoperative chemo-radiotherapy for carcinoma of the esophagus 48
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group 48
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients 48
A true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10 48
Novel investigational drugs for gastric cancer 47
Totale 5.883
Categoria #
all - tutte 41.656
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.656


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019311 0 0 0 0 0 0 0 0 0 0 282 29
2019/20201.393 246 219 35 22 196 29 266 101 134 73 55 17
2020/20211.763 165 19 193 85 342 13 234 186 39 217 171 99
2021/20221.456 134 10 16 24 528 8 30 48 51 61 125 421
2022/20233.338 432 61 45 262 364 257 15 194 1.592 14 56 46
2023/20241.041 107 36 59 119 446 168 16 31 16 19 24 0
Totale 10.911